Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't sell on Friday. CEO may have the updates next week.
The graph looks great. What is the story here? Why it dropped from above $10 to .04s ? Someone cares to explain? greatly appreciate.
Thanks. I'll wait until after Dec 18 to load my shares...
TK
When will the AS increases to 10Bil to take affect, is that the end of Dec, 2014?
TK
I called several minutes late, and it was ended in a couple of minutes after that.
Did he mention anythings about the questions sent in at all?
TIA
TK
Terry,
I wasn't trying to compare the technologies between the two companies.
My point was GENE would be a better investment for your money in the short term and SVON is because SVON is still very far from market, 2-3 years down the road maybe. GENE already have 4mil revenue, it projected to have around 16mil revenue in 2015, they may profit next year.
They both have around 10mil market cap.
So, your money if put in GENE is, in short term, much better than put in SVON. SVON would face more uncertainty than GENE because of the trials ahead of them.
JMHO.
TK
SVON is still expensive at 10mil market cap, provided the company is only in development stages. Look at GENE, about same market cap, it has a product with 4Mil revenue annually in 2014, forecast 16mil in 2015
I don't have PM. It was more than $1 in Sept. More than 1 is plural, plural means multi
I think it has touched bottom earlier today. It was multi dollars stock earlier this month.
This one is still undiscovered just like Can-Fite... it will have its day soon! Grossly undervalued.
should be much more than 71Mil. I called and asked them twice (each time spoke to different ladies) yesterday and the day before that about the current Outstanding shares, they told me to call me back after they called the TA. I still haven't heard anything from them... so I guess it would have increase to a big number by now since we see all the dilution going on every day.
Dario™ @my_dario · 31m 31 minutes ago
We are working now for FDA approval in the U.S., @DiabeticDig! Stay tuned!
Russell, if you read this message board, move your ask BMAK up, why are you selling shares at this level???
Rush is selling shares through BMAK currently, i bet.
I'm no bash or pump, but Russ isn't a reliable person. I called the company for a couple of times, he said a PR will be out last week, but wasn't.
Does anyone call the company today? wonder why news isn't out yet. I called last Friday and was told the news is currently processing. He said they wouldn't release it on Friday, so I guess it would be on Monday, but still not... hope it will be out soon ...
I hope there will be a PR released tomorrow to explain why they need to raise the AS to 10bil. This will wipe out the PPS.
I hope it won't get pass.
did you happen to ask them what is the current O/S? last week, he told me 71Mil, not sure if the company diluted today or not... Thanks.
Agree! If dilution happens, the volume is much bigger and it usually slap the bids. Volume in the last couple of days is normal, around 14Mil a day.
News will be out this week, or next week. Under 1Mil market Cap. Very Cheap.
I talked with him last week and got the same info.
He said the hemp-based MigraPure is currently in production.
I asked him if he has the time line for that production. He said they will have it in a couple of days and will PR it.
Asher was out. There is no share left per that filing.
News will be out this week or next week per company.
I know 4Bil is big. He acknowledge it, and said the company tries to do one thing at a time. It sounds to me the company will work on that 4Bil after they're done with production of the hemp-based over-the-counter migrain medication. You can call the company up and find out yourself. I used the phone listed on their website. There's someone picked up right away the first time I called.
Tk.
He said the A/S still 4Bil shares. He said the company tries to do one thing at a time. I didn't even ask why it's that high, he just said that. The MigraPure with hemp-based formulation is currently in production. They will update on that next week or the week after.
Tk
I called the company last week, they said the current OS is 71M.
Negative from Prospectus (good warning, so we're beware ):
Our Financial Condition
As of June 30, 2014, we had approximately $1,819,000 in cash or cash equivalents and a total stockholders’ deficit accumulated since our inception of approximately $26 million. Our cash on hand was increased in September 2014 when we consummated a private placement in which we raised approximately $4.2 million of gross proceeds. We refer to this private placement herein as the September 2014 Private Placement. Pursuant to the registration statement of which this prospectus forms a part, we are registering the shares of our common stock underlying the Series A Convertible Preferred Stock and warrants issued in the September 2014 Private Placement.
We have not yet generated any material revenues from our operations, and we currently have very limited sources of recurring sales and are therefore dependent upon external sources for financing our operations. There can be no assurance that we will generate revenues or that we will be able to obtain the necessary financing to continue our operations. As a result, our independent registered public accounting firm has expressed in its auditors’ report on the financial statements for the year ended December 31, 2013 included as part of this prospectus a substantial doubt regarding our ability to continue as a going concern.
According to our management’s estimates, based on our budget and the initial launch of our commercial sales as well as the reduction of our operating expenses during 2014, we believe that we will have sufficient resources to continue our activity into March 2015. However, if we are not able to commercially launch Dario™ or meet our commercial sales targets, and if we are unable to obtain additional capital resources, we may not be able to continue activities beyond that time and to further our business plan. If we cannot continue as a going concern, our stockholders would lose their entire investment in our company.
Positive from Prospectus:
In April 2014, we announced the receipt of reimbursement coverage for the use of the Dario™ Smart Meter in Italy, making 600,000 Italians eligible for reimbursement coverage. In June 2014, we were granted (effective September 1, 2014) reimbursement status in England, Wales, Scotland and Northern Ireland for strips and lancets to be utilized together with the Dario™ Smart Meter. We are actively pursuing reimbursement coverage in other jurisdictions.
We are presently pursuing patent applications in multiple jurisdictions covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. On August 5 2014, we were issued a U.S. patent (No. 8,797,180) relating to how the Dario™ blood glucose monitor draws power from and transmits data to a smart phone via the audio jack port. We believe this represents a critical intellectual property recognition and a significant initial validation of our intellectual property efforts.
Based on positive initial market feedback, we are presently working towards ramping up manufacturing and sales and marketing activities for Dario™ in the hopes of establishing recurring revenue from sales. For the remainder of 2014, we expect to continue with the soft launch of Dario™, expanding the soft launch to other jurisdictions, and to prepare for our longer-term roll-out of Dario™. Over time, we expect to add additional features and functionality in making Dario™ the new standard of care in diabetes data management.
to prevent MMs borrowing your shares, please set your sell orders to much higher price, say .15+ so we can have the shares locked... this would help our PPS to just go up from here...
News issued on October 15, 2014
Ludlow Research Issues Opinion on PMBSD Based on Cannabis-Based Epilepsy Symptom Research, Launch of Migraine Product
SCHOFIELD, Wis., Oct. 15, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBSD), a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced that Ludlow Research has issued a research opinion of the Company based on the pending launch of its rebranded migraine product, MigraPure, the development of a hemp-based epilepsy symptom treatment, and the Company's current valuation.
The Company recently announced development of an over-the-counter medication using cannabinoid-rich hemp, for the treatment of epilepsy symptoms. Recent studies show CBD to be effective in the treatment of the symptoms of epilepsy.
"As PuraMed prepares to re-launch its natural over-the-counter migraine product as MigraPure and develops its hemp-based formulation, the company could create a medication with wide ranging benefits for people who suffer with epilepsy and who suffer chronic migraines," said Tom Bustamonte, of Ludlow Research.
In addition, the Company recently announced completion of the first batch of its patented, sublingual MigraPure® Advanced Migraine Relief feverfew and ginger gel with an enhanced flavor.
MigraPure Advanced Migraine Relief is a doctor-recommended homeopathic formulation that has been clinically tested (originally tested as LipiGesic® M) by headache experts and found highly effective in the treatment of acute migraine pain and associated symptoms. Packaged in pre-measured UnitDose sachets, MigraPure's gel is administered under the tongue, which allows active ingredients to reach the bloodstream faster and more effectively than traditional oral medications.
PMBSD current has approximately 70 million common shares issued and outstanding, and is fully reporting with the SEC.
Ludlow Research issued their "speculative" opinion on PMBSD based on research in areas of epilepsy symptom treatment using cannabinoid-rich hemp, the pending re-launch of the over-the-counter migraine product, MigraPure advanced migraine relief, and the current low market cap value of the Company, which is just under $300,000.
To download the full report, and access risks, disclosers, and potential outlook visit www.ludlowresearch.com/reports.html
About Ludlow Research
Ludlow Equity Research is a New York based equity research firm focused on providing our clients, and individual readers, with in-depth research coverage and opinions on the small-cap securities market. For over 14 years, we have aimed to provide our subscribers a simple way of evaluating the current and potential value of small-cap stocks, and any risks that may affect those valuations going forward. Our goal is to provide traders with an easy way to make investment decisions based on current and future valuations. Ludlow Equity Research is a division of Ludlow Capital, Inc. www.ludlowresearch.com
Ludlow Research provides research coverage and host of investor awareness services for publicly traded small cap equities.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products, which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts.
In addition to the rebranding of LipiGesic M as MigraPure, PMBS plans to launch additional hemp-based, cannabinoid-enhanced, anti-inflammatory and anxiolytic products as it moves forward in the development of its cannabinoid product line. www.PuramedBioScience.com
Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contacts:
Russ Mitchell
PuraMed BioScience, Inc.
715.359.6373
Melissa J. Diaz
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com
iTechiie, Would you help sticky the PR from Oct. 15 and 10 while they're not showing in the ihub yet? Please update the SS in the intro, it would help the PPS a lot. Thanks.
it would help if we sticky that PR so everyone can see. I bought in because of that PR Elections is next week... MMJ stocks, including PMBSD, should go up from here. Market Cap is under $1M... cheap still.
Wonder why this news on Oct 15 didn't shown on ihup:
Ludlow Research Issues Opinion on PMBSD Based on Cannabis-Based Epilepsy Symptom Research, Launch of Migraine Product
SCHOFIELD, Wis., Oct. 15, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBSD), a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced that Ludlow Research has issued a research opinion of the Company based on the pending launch of its rebranded migraine product, MigraPure, the development of a hemp-based epilepsy symptom treatment, and the Company's current valuation.
The Company recently announced development of an over-the-counter medication using cannabinoid-rich hemp, for the treatment of epilepsy symptoms. Recent studies show CBD to be effective in the treatment of the symptoms of epilepsy.
"As PuraMed prepares to re-launch its natural over-the-counter migraine product as MigraPure and develops its hemp-based formulation, the company could create a medication with wide ranging benefits for people who suffer with epilepsy and who suffer chronic migraines," said Tom Bustamonte, of Ludlow Research.
In addition, the Company recently announced completion of the first batch of its patented, sublingual MigraPure® Advanced Migraine Relief feverfew and ginger gel with an enhanced flavor.
MigraPure Advanced Migraine Relief is a doctor-recommended homeopathic formulation that has been clinically tested (originally tested as LipiGesic® M) by headache experts and found highly effective in the treatment of acute migraine pain and associated symptoms. Packaged in pre-measured UnitDose sachets, MigraPure's gel is administered under the tongue, which allows active ingredients to reach the bloodstream faster and more effectively than traditional oral medications.
PMBSD current has approximately 70 million common shares issued and outstanding, and is fully reporting with the SEC.
Ludlow Research issued their "speculative" opinion on PMBSD based on research in areas of epilepsy symptom treatment using cannabinoid-rich hemp, the pending re-launch of the over-the-counter migraine product, MigraPure advanced migraine relief, and the current low market cap value of the Company, which is just under $300,000.
To download the full report, and access risks, disclosers, and potential outlook visit www.ludlowresearch.com/reports.html
About Ludlow Research
Ludlow Equity Research is a New York based equity research firm focused on providing our clients, and individual readers, with in-depth research coverage and opinions on the small-cap securities market. For over 14 years, we have aimed to provide our subscribers a simple way of evaluating the current and potential value of small-cap stocks, and any risks that may affect those valuations going forward. Our goal is to provide traders with an easy way to make investment decisions based on current and future valuations. Ludlow Equity Research is a division of Ludlow Capital, Inc. www.ludlowresearch.com
Ludlow Research provides research coverage and host of investor awareness services for publicly traded small cap equities.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products, which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts.
In addition to the rebranding of LipiGesic M as MigraPure, PMBS plans to launch additional hemp-based, cannabinoid-enhanced, anti-inflammatory and anxiolytic products as it moves forward in the development of its cannabinoid product line. www.PuramedBioScience.com
Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contacts:
Russ Mitchell
PuraMed BioScience, Inc.
715.359.6373
Melissa J. Diaz
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com
same here, set all my sell at .25+ so the MMs can't borrow my shares
no selling...great! shorts get burned.
$10mil not even the end of October yet. Online games company would have much bigger profit margin than the conventional casinos... think about it.
This is so great. The Market Cap is less than $1M at the current PPS
Can you share what they told you?
Take a look at ITNS & DRIO
TK
You just said exactly what I wanted to say... long ITNS...
Snorenz on Amazon.com http://www.amazon.com/Snorenz-through-products-MedGen-entire/dp/B00028MH10
tk
Yeah. Today is a good day to buy low float weeds: EAPH, LVVV, SING, VTMB
Low float WEED plays: EAPH, VTMB, LVVV, SING